TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Fundamental Analysis
NYSE:TEVA - New York Stock Exchange, Inc. - US8816242098 - ADR
Taking everything into account, TEVA scores 4 out of 10 in our fundamental rating. TEVA was compared to 195 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of TEVA while its profitability can be described as average. TEVA has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
TEVA had positive earnings in the past year.
In the past year TEVA had a positive cash flow from operations.
In the past 5 years TEVA reported 4 times negative net income.
In the past 5 years TEVA always reported a positive cash flow from operatings.
1.2 Ratios
TEVA has a better Return On Assets (-1.15%) than 81.72% of its industry peers.
TEVA has a better Return On Equity (-7.49%) than 79.57% of its industry peers.
TEVA's Return On Invested Capital of 10.36% is amongst the best of the industry. TEVA outperforms 88.17% of its industry peers.
The Average Return On Invested Capital over the past 3 years for TEVA is significantly below the industry average of 43.99%.
The 3 year average ROIC (8.01%) for TEVA is below the current ROIC(10.36%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.15% | ||
| ROE | -7.49% | ||
| ROIC | 10.36% |
ROA(3y)-1.99%
ROA(5y)-3.12%
ROE(3y)-11.58%
ROE(5y)-16.34%
ROIC(3y)8.01%
ROIC(5y)7.1%
1.3 Margins
TEVA has a better Operating Margin (22.79%) than 88.71% of its industry peers.
TEVA's Operating Margin has improved in the last couple of years.
TEVA has a Gross Margin of 50.74%. This is in the better half of the industry: TEVA outperforms 61.29% of its industry peers.
In the last couple of years the Gross Margin of TEVA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.79% | ||
| PM (TTM) | N/A | ||
| GM | 50.74% |
OM growth 3Y5.53%
OM growth 5Y5.95%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.49%
GM growth 5Y2.73%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TEVA is creating some value.
The number of shares outstanding for TEVA remains at a similar level compared to 1 year ago.
Compared to 5 years ago, TEVA has more shares outstanding
Compared to 1 year ago, TEVA has an improved debt to assets ratio.
2.2 Solvency
TEVA has an Altman-Z score of 0.58. This is a bad value and indicates that TEVA is not financially healthy and even has some risk of bankruptcy.
TEVA has a Altman-Z score (0.58) which is comparable to the rest of the industry.
TEVA has a debt to FCF ratio of 27.45. This is a negative value and a sign of low solvency as TEVA would need 27.45 years to pay back of all of its debts.
TEVA has a Debt to FCF ratio of 27.45. This is in the better half of the industry: TEVA outperforms 79.57% of its industry peers.
A Debt/Equity ratio of 2.61 is on the high side and indicates that TEVA has dependencies on debt financing.
TEVA has a Debt to Equity ratio of 2.61. This is amonst the worse of the industry: TEVA underperforms 81.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.61 | ||
| Debt/FCF | 27.45 | ||
| Altman-Z | 0.58 |
ROIC/WACC1.45
WACC7.14%
2.3 Liquidity
A Current Ratio of 0.89 indicates that TEVA may have some problems paying its short term obligations.
With a Current ratio value of 0.89, TEVA is not doing good in the industry: 88.71% of the companies in the same industry are doing better.
A Quick Ratio of 0.59 indicates that TEVA may have some problems paying its short term obligations.
TEVA has a worse Quick ratio (0.59) than 93.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.89 | ||
| Quick Ratio | 0.59 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 22.47% over the past year.
Looking at the last year, TEVA shows a small growth in Revenue. The Revenue has grown by 6.17% in the last year.
Measured over the past years, TEVA shows a decrease in Revenue. The Revenue has been decreasing by -3.42% on average per year.
EPS 1Y (TTM)22.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15%
Revenue 1Y (TTM)6.17%
Revenue growth 3Y-1.65%
Revenue growth 5Y-3.42%
Sales Q2Q%12.52%
3.2 Future
TEVA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.44% yearly.
TEVA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.39% yearly.
EPS Next Y-2.98%
EPS Next 2Y5.53%
EPS Next 3Y5.44%
EPS Next 5YN/A
Revenue Next Year7.14%
Revenue Next 2Y5.79%
Revenue Next 3Y4.39%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 7.88, the valuation of TEVA can be described as very cheap.
Based on the Price/Earnings ratio, TEVA is valued cheaper than 94.09% of the companies in the same industry.
TEVA's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.96.
The Price/Forward Earnings ratio is 7.69, which indicates a rather cheap valuation of TEVA.
92.47% of the companies in the same industry are more expensive than TEVA, based on the Price/Forward Earnings ratio.
TEVA's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.11.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.88 | ||
| Fwd PE | 7.69 |
4.2 Price Multiples
88.71% of the companies in the same industry are more expensive than TEVA, based on the Enterprise Value to EBITDA ratio.
TEVA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. TEVA is cheaper than 81.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.57 | ||
| EV/EBITDA | 8.54 |
4.3 Compensation for Growth
TEVA has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.53%
EPS Next 3Y5.44%
5. Dividend
5.1 Amount
TEVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TEVA PHARMACEUTICAL-SP ADR
NYSE:TEVA (1/17/2025, 8:04:00 PM)
After market: 21.89 -0.03 (-0.14%)21.92
+0.24 (+1.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners8.65%
Inst Owner Change0.04%
Ins Owners0.56%
Ins Owner Change-1.21%
Market Cap24.83B
Analysts42.22
Price Target0.06 (-99.73%)
Short Float %2.41%
Short Ratio2.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.03%
Min EPS beat(2)-8.98%
Max EPS beat(2)4.92%
EPS beat(4)2
Avg EPS beat(4)5.71%
Min EPS beat(4)-8.98%
Max EPS beat(4)28.49%
EPS beat(8)3
Avg EPS beat(8)-2.49%
EPS beat(12)5
Avg EPS beat(12)-2.1%
EPS beat(16)7
Avg EPS beat(16)-1.87%
Revenue beat(2)1
Avg Revenue beat(2)0.22%
Min Revenue beat(2)-0.39%
Max Revenue beat(2)0.82%
Revenue beat(4)3
Avg Revenue beat(4)2.83%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)9.4%
Revenue beat(8)4
Avg Revenue beat(8)0.19%
Revenue beat(12)4
Avg Revenue beat(12)-1.75%
Revenue beat(16)5
Avg Revenue beat(16)-2.14%
PT rev (1m)2.03%
PT rev (3m)8.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.51%
EPS NY rev (1m)0%
EPS NY rev (3m)0.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.29%
Revenue NY rev (1m)1%
Revenue NY rev (3m)1.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.88 | ||
| Fwd PE | 7.69 | ||
| P/S | 1.52 | ||
| P/FCF | 36.57 | ||
| P/OCF | 21.26 | ||
| P/B | 3.91 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.54 |
EPS(TTM)2.78
EY12.68%
EPS(NY)2.85
Fwd EY13.01%
FCF(TTM)0.6
FCFY2.73%
OCF(TTM)1.03
OCFY4.7%
SpS14.38
BVpS5.61
TBVpS-13.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.15% | ||
| ROE | -7.49% | ||
| ROCE | 13.12% | ||
| ROIC | 10.36% | ||
| ROICexc | 11.25% | ||
| ROICexgc | 62.08% | ||
| OM | 22.79% | ||
| PM (TTM) | N/A | ||
| GM | 50.74% | ||
| FCFM | 4.17% |
ROA(3y)-1.99%
ROA(5y)-3.12%
ROE(3y)-11.58%
ROE(5y)-16.34%
ROIC(3y)8.01%
ROIC(5y)7.1%
ROICexc(3y)8.75%
ROICexc(5y)7.67%
ROICexgc(3y)44.24%
ROICexgc(5y)41.47%
ROCE(3y)10.15%
ROCE(5y)9.04%
ROICexcg growth 3Y8.62%
ROICexcg growth 5Y4.84%
ROICexc growth 3Y12.61%
ROICexc growth 5Y12.54%
OM growth 3Y5.53%
OM growth 5Y5.95%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.49%
GM growth 5Y2.73%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.61 | ||
| Debt/FCF | 27.45 | ||
| Debt/EBITDA | 3.46 | ||
| Cap/Depr | 45.28% | ||
| Cap/Sales | 3% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 24.37% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.89 | ||
| Quick Ratio | 0.59 | ||
| Altman-Z | 0.58 |
F-Score6
WACC7.14%
ROIC/WACC1.45
Cap/Depr(3y)43.26%
Cap/Depr(5y)39.48%
Cap/Sales(3y)3.51%
Cap/Sales(5y)3.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15%
EPS Next Y-2.98%
EPS Next 2Y5.53%
EPS Next 3Y5.44%
EPS Next 5YN/A
Revenue 1Y (TTM)6.17%
Revenue growth 3Y-1.65%
Revenue growth 5Y-3.42%
Sales Q2Q%12.52%
Revenue Next Year7.14%
Revenue Next 2Y5.79%
Revenue Next 3Y4.39%
Revenue Next 5YN/A
EBIT growth 1Y19.2%
EBIT growth 3Y3.78%
EBIT growth 5Y2.33%
EBIT Next Year27.4%
EBIT Next 3Y12.39%
EBIT Next 5YN/A
FCF growth 1Y42.95%
FCF growth 3Y9.69%
FCF growth 5Y-14.05%
OCF growth 1Y10.4%
OCF growth 3Y4%
OCF growth 5Y-10.97%